Alnylam Says New Data From Helios-B Phase 3 Study Demonstrate Lower Rates Of Gastrointestinal Events In ATTR-CM Patients Treated With Vutrisiran
View all comments(0)
Sept 28 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:
NEW DATA FROM HELIOS-B PHASE 3 STUDY DEMONSTRATE LOWER RATES OF GASTROINTESTINAL EVENTS IN ATTR-CM PATIENTS TREATED WITH VUTRISIRAN
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.